

**Policy: 267**

**Section: Medical Benefit Policy**

**Subject: Amniotic Membrane Transplant for Ocular Surface Defects and Amniotic Injections**

---

**I. Policy:** Amniotic Membrane Transplant for Ocular Surface Defects and Amniotic Injections

**II. Purpose/Objective:**

To provide a policy of coverage regarding Amniotic Membrane Transplant for Ocular Surface Defects and Amniotic Injections

**III. Responsibility:**

- A. Medical Directors
- B. Medical Management

**IV. Required Definitions**

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

**V. Additional Definitions**

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

**Medicaid Business Segment**

Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

- (i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
- (ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.

- (iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.

**DESCRIPTION:**

Amniotic membrane transplantation (AMT) is a procedure that utilizes amniotic membrane tissue to reconstruct damaged ocular surfaces and promote healing of corneal, conjunctival, and eyelid tissues after injury due to trauma, disease, or surgery. Human amniotic membrane grafts may also be used to treat lower extremity diabetic skin ulcers.

**INDICATIONS:**

Preserved human amniotic membrane transplantation may be considered medically necessary for the treatment of ocular surface defects including, but not limited to:

- Bullous keratopathy
- Chemical or thermal burns to ocular surface
- Corneal ulcerations
- Pterygium (either primary and/or recurrent)
- Stevens-Johnson syndrome
- Limbal cell deficiency
- Persistent epithelial defects
- Conjunctival surface reconstruction
- Herpes zoster ophthalmicus

Human amniotic membrane grafts will be considered medically necessary for the treatment of non-healing lower-extremity diabetic skin ulcers. **(See also: MP075)** Examples of these human amniotic membrane products include, but are not limited to:

- AmnioBand® Membrane
- Biovance®
- Epifix®
- GrafixCore™)
- GrafixPrime™

**EXCLUSIONS:** Injection of human amniotic fluid is considered investigational for all indications including, but not limited to osteoarthritis and plantar fasciitis. There is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this service on health outcomes when compared to established treatments or technologies, and therefore are considered to be **NOT COVERED**.

**Medicaid Business Segment:**

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

**CODING ASSOCIATED WITH:** Amniotic Membrane Transplant for Ocular Surface Defects and Amniotic Injections  
*The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at [www.cms.gov](http://www.cms.gov) or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements*

- 65778 – Placement of amniotic membrane on the ocular surface; without sutures
- 65779 - single layer, sutured
- 65780 – Ocular surface reconstruction; amniotic membrane transplantation, multiple layers
- 65781 limbal stem cell allograft (e.g., cadaveric or living donor)
- 65782 limbal conjunctival autograft (includes obtaining graft)
- V2790 Amniotic membrane for surgical reconstruction, per procedure
- Q4132 Grafix Core, per sq cm
- Q4133 Grafix prime, grafixpl prime, stravax and stravaxpl, per square centimeter
- Q4151 AmnioBand or Guardian, per sq cm
- Q4154 Biovance, per sq cm

Q4168 AmnioBand, 1 mg  
Q4186 Epifix, per square centimeter  
Q4187 Epicord, per square centimeter

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

**LINE OF BUSINESS:**

**Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supersede this policy. For PA Medicaid Business segment, this policy applies as written.**

**REFERENCES:**

- Geisinger Technology Assessment Committee Triage review July 2012
- Chawla, B, Sharma, N, Tandon, et al. Comparative evaluation of phototherapeutic keratectomy and amniotic membrane transplantation for management of symptomatic chronic bullous keratopathy. *Cornea*. 2010;29(9):976-979.
- Tandon, R, Gupta, N, Kalaivani, M, et al. Amniotic membrane transplantation as an adjunct to medical therapy in acute ocular burns. *Br J Ophthalmol*. 2010.
- Altiparmak, UE, Oflu, Y, Yildiz, EH, et al. Prospective comparison of two suturing techniques of amniotic membrane transplantation for symptomatic bullous keratopathy. *Am J Ophthalmol*. 2009;147(3):442-446.
- Xia, Z, X, Lan, YQ, Wang, M, Xiao, JH, Guo, H, and Hu, Y, X. Analysis of efficacy of three different operation modes for preventing recurrence of pterygium. *International Journal of Ophthalmology*. 2008;8(8):1623-1625.
- Tang, GF, Yan, MN, Wang, YL, et al. Comparison between the effects of ocular surface reconstruction by fresh and preserved amniotic membranes. *Journal of Clinical Rehabilitative.Tissue Engineering. Research*. 2007;11(16):3122-3+3130.
- Khokhar, S, Natung, T, Sony, P, et al. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. *Cornea*. 2005;24(6):654-660.
- Tamhane, A, Vajpayee, RB, Biswas, NR, et al. Evaluation of amniotic membrane transplantation as an adjunct to medical therapy as compared with medical therapy alone in acute ocular burns. *Ophthalmology*. 2005;112(11):1963-1969.
- Yoon, KC, Im, SK, Kim, JC, et al. Prognosis of paraquat-induced ocular surface injury: therapeutic effect of amniotic membrane transplantation. *Cornea*. 2009;28(5):520-523.
- Gicquel, JJ, Bejjani, RA, Ellies, P, et al. Amniotic membrane transplantation in severe bacterial keratitis. *Cornea*. 2007;26(1):27-33.
- Vyas, S, Rathi, V. Combined phototherapeutic keratectomy and amniotic membrane grafts for symptomatic bullous keratopathy. *Cornea*. 2009;28(9):1028-1031.
- Georgiadis, NS, Ziakas, NG, Boboridis, KG, et al.. Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. *Clin Experiment Ophthalmol*. 2008;36(2):130-135.
- Saw VP, Minassian D, Dart JK, et al. Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group. *B J Ophthalmol* 2007;91(8):1042-1047.
- Solomon A, Meller D, et al. Amniotic Membrane Grafts for Nontraumatic Corneal Perforations, Descemetocelles, and Deep Ulcers. *Ophthalmology* 2002;109:694-703
- Gicquel, JJ, Bejjani, RA, Ellies, P, et al. Amniotic membrane transplantation in severe bacterial keratitis. *Cornea*. 2007;26(1):27-33.
- Dighiero, PL, Mercié, M, and Gicquel, J. Early use of amniotic membrane transplantation combined with topical steroids in severe bacterial keratitis. *IOVS*. 2005;45ARVO-abstract. Cochrane Library
- Lin, HC, Chu, PH, Kuo, YH, and Shen, SC. Clinical experience in managing *Fusarium solani* keratitis. *Int J Clin Pract*. 2005;59(5):549-554.
- Vyas, S, Rathi, V. Combined phototherapeutic keratectomy and amniotic membrane grafts for symptomatic bullous keratopathy. *Cornea*. 2009;28(9):1028-1031.

- Georgiadis, NS, Ziakas, NG, Boboridis, KG, et al. Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. *Clin Experiment Ophthalmol.* 2008;36(2):130-135.
- Lee, HI, Ha, SW, and Kim, JC. A novel application of amniotic membrane in patients with bullous keratopathy. *J Korean Med Sci.* 2006;21(2):324-328.
- Zemba, M, Andrei, S, Cucu, B, et al. Amniotic membrane transplantation in palliative treatment of bullous keratopathy. *Oftalmologia.* 2006;50(4):51-53.
- Chansanti, O, Horatanaruang, O. The results of amniotic membrane transplantation for symptomatic bullous keratopathy. *J Med Assoc Thai.* 2005;88 Suppl 9:S57-S62.
- Muller, M, Meltendorf, C, Mirshahi, A, and Kohnen, T. Use of multilayer amniotic membrane as first therapy for penetrating corneal ulcers. *Klin Monatsbl Augenheilkd.* 2009;226(8):640-644.
- Bialasiewicz, AA, Shenoy, R, Al-Muniri, A, and Thakral, A. Diseases of the adnexa in the tropics: amnion membrane transplantation for noninfectious trachoma-associated corneal ulcers. *Ophthalmologe.* 2006;103(11):940-944.
- Lopez-Garcia, JS, Rivas, JL, et al. Histopathologic limbus evolution after alkaline burns. *Cornea.* 2007;26(9):1043-1048.
- Prabhasawat, P, Tesavibul, N, et al. Efficacy of amniotic membrane patching for acute chemical and thermal ocular burns. *J Med Assoc Thai.* 2007;90(2):319-326.
- Tejwani, S, Kolari, RS, Sangwan, VS, Rao, GN. Role of amniotic membrane graft for ocular chemical and thermal injuries. *Cornea.* 2007;26(1):21-26.
- Arora, R, Mehta, D, Jain, V. Amniotic membrane transplantation in acute chemical burns. *Eye (Lond).* 2005;19(3):273-278.
- Ivekovic, R, Tedeschi-Reiner, E, Novak-Laus, K, et al. Limbal graft and/or amniotic membrane transplantation in the treatment of ocular burns. *Ophthalmologica.* 2005;219(5):297-302.
- Seitz, B, Das, S, Sauer, R, et al. Amniotic membrane transplantation for persistent corneal epithelial defects in eyes after penetrating keratoplasty. *Eye.* 2009;23(4):840-848.
- Nubile, M, Dua, HS, Lanzini, TE, et al. Amniotic membrane transplantation for the management of corneal epithelial defects: an in vivo confocal microscopic study. *Br J Ophthalmol.* 2008;92(1):54-60.
- Kheirkhah, A, Casas, V, Raju, VK, Tseng, SC. Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency. *Am J Ophthalmol.* 2008;145(5):787-794.
- Lopez-Garcia, JS, Rivas, L, and Garcia-Lozano, I. Moderate limbal deficiency in patients with congenital aniridia treated with amniotic membrane transplantation. *Arch Soc Esp Oftalmol.* 2005;80(9):517-523.
- Im, SK, Lee, KH, and Yoon, KC. Combined ethylenediaminetetraacetic acid chelation, phototherapeutic keratectomy and amniotic membrane transplantation for treatment of band keratopathy. *Korean J Ophthalmol.* 2010;24(2):73-77.
- Rao, A, Sridhar, U, and Gupta, AK. Amniotic membrane transplant with superficial keratectomy in superficial corneal degenerations: efficacy in a rural population of north India. *Indian J Ophthalmol.* 2008;56(4):297-302.
- Vasseneix, C, Toubreau, D, Brasseur, G, and Muraine, M. Surgical management of nontraumatic corneal perforations: an 8-year retrospective study. *J Fr Ophtalmol.* 2006;29(7):751-762.
- Wylegala, E, Tarnawska, D. Amniotic membrane transplantation with cauterization for keratoconus complicated by persistent hydrops in mentally retarded patients. *Ophthalmology.* 2006;113(4):561-564.
- Gunduz, K, Ucakhan, OO, Kanpolat, A, Gunalp, I. Nonpreserved human amniotic membrane transplantation for conjunctival reconstruction after excision of extensive ocular surface neoplasia. *Eye (Lond).* 2006;20(3):351-357.
- Shammas, MC, Lai, EC, Sarkar, JS, et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. *Am J Ophthalmol.* 2010;149(2):203-213.
- Yildiz, EH, Nurozler, AB, Ozkan, AN, et al. Amniotic membrane transplantation: indications and results. *Eur J Ophthalmol.* 2008;18(5):685-690.
- Saw, VP, Minassian, D, Dart, JK, et al. Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group. *Br J Ophthalmol.* 2007;91(8):1042-1047.

Pachigolla, G, Prasher, P, Di Pascuale, MA, et al. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. *Eye Contact Lens*. 2009;35(4):172-175.

Park, JH, Jeoung, JW, Wee, WR, et al. Clinical efficacy of amniotic membrane transplantation in the treatment of various ocular surface diseases. *Cont Lens Anterior Eye*. 2008;31(2):73-80.

Maharajan, VS, Shanmuganathan, V, Currie, A, et al. Amniotic membrane transplantation for ocular surface reconstruction: indications and outcomes. *Clin Experiment Ophthalmol*. 2007;35(2):140-147.

Chandra, A, Maurya, OP, Reddy, B, Kumar, et al. Amniotic membrane transplantation in ocular surface disorders. *J Indian Med Assoc*. 2005;103(7):364-6, 368.]

Al-Kharashi, S, Al-Khawaja, A, Gonnah, et al. Microbial keratitis after amniotic membrane transplantation. *Int Ophthalmol*. 2005;26(3):73-76.

Meller D, Pauklin M, Thomasen H, Westekemper H, Steuhl KP. Amniotic membrane transplantation in the human eye. *Dtsch Arztebl Int*. 2011 Apr;108(14):243-8

Clearfield E, Muthappan V, Wang X, Kuo IC. Conjunctival autograft for pterygium. *Cochrane Database Syst Rev*. 2016;2:CD011349

DiDomenico LA, Orgill DP, Galiano RD, et al. Aseptically processed placental membrane improves healing of diabetic foot ulcerations: prospective, randomized clinical trial. *Plast Reconstr Surg Glob Open*. Oct 2016;4(10):e1095

Snyder RJ, Shimozaki K, Tallis A, et al. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. *Wounds*. Mar 2016;28(3):70-77.

Tettelbach, WW, Cazzell, SS, Sigal, FF, Caporusso, JJ et al A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers.. *Int Wound J*. 2019 Feb;16(1):122-130

Cazzell, S., Stewart, J., Agnew, P. S., Senatore, J. et al) Randomized Controlled Trial of Micronized Dehydrated Human Amnion/Chorion Membrane (dHACM) Injection Compared to Placebo for the Treatment of Plantar Fasciitis. *Foot & Ankle International*. 2018 39(10), 1151–1161

Ananian, CC, Dhillon, YY, Van Gils, CC, Lindsey, DD et al.. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers. *Wound Repair Regen*, 2018 Aug 12;26(3).

Liu J, Li L, Li X, et al. Effectiveness of cryopreserved amniotic membrane transplantation in corneal ulceration: A meta-analysis. *Cornea*. 2019 Jan 29

Yin HY, Cheng AMS, Tighe S, et al. Self-retained cryopreserved amniotic membrane for treating severe corneal ulcers: a comparative, retrospective control study. *Sci Rep*. Oct 12 2020; 10(1): 17008.

This policy will be revised as necessary and reviewed no less than annually.

**Devised:** 7/12

**Revised:** 7/19 (add indications and exclusions)

**Reviewed:** 8/13, 8/14; 8/15; 7/16, 7/17, 6/18, 7/20, 7/21, 7/22

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.